New Age Alpha Advisors LLC Buys Shares of 28,264 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

New Age Alpha Advisors LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 28,264 shares of the biopharmaceutical company’s stock, valued at approximately $1,351,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in HALO. Norges Bank acquired a new stake in Halozyme Therapeutics during the fourth quarter worth $60,054,000. Raymond James Financial Inc. purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth $21,838,000. Vanguard Group Inc. increased its position in shares of Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock worth $634,999,000 after purchasing an additional 386,618 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after purchasing an additional 251,711 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Halozyme Therapeutics by 60.0% in the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock valued at $31,112,000 after buying an additional 243,940 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 31,697 shares of company stock valued at $1,754,451. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Down 1.0 %

Shares of NASDAQ HALO opened at $63.84 on Monday. The stock has a market cap of $7.89 billion, a P/E ratio of 18.61, a PEG ratio of 0.42 and a beta of 1.32. The business’s fifty day simple moving average is $59.16 and its 200-day simple moving average is $54.85. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.